Patients with NSCLC and cachexia who received PD‐1/L1 monotherapy tended to have worse survival than those without cachexia irrespective of presence of ghrelin, CRP, PTX‐3, and OPN. Here, GHRL is linked to non-small cell lung carcinoma.